Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item
3. Quantitative and Qualitative Disclosures About Market Risk.
As
of June 30, 2026, we had cash and cash equivalents of $741,324 including cash, cash equivalents and market investments. Our primary exposure
to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. We are exposed
to market risk related to the marketability of investments in private companies, consisting of our AlloTera Therapeutics common stock
and our Trimmune shares, reported within Investments in the accompanying condensed balance sheet. Until such time as these shares become
publicly traded, we will have limited ability to liquidate these securities.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.